CC
NTLA icon

Casdin Capital’s Intellia Therapeutics NTLA Stock Holding History

Casdin Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.38M – 40
2024
Q1 		$1.38M Buy
+50,000
New +$1.39M 0.1% 34

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Casdin Capital's NTLA Position: Q2 2026 in Review

Casdin Capital held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 355,000 shares worth $6.01M. The position accounts for 0.3% of the portfolio, ranked #31.

Casdin Capital first reported a position in NTLA in Q3 2022 and has held it in 13 quarters since. The position peaked at $52M in Q2 2023. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Casdin Capital held 355,000 shares of Intellia Therapeutics worth $6.01M as of Q2 2026.
  • Casdin Capital left its Intellia Therapeutics share count unchanged in Q2 2026.
  • Intellia Therapeutics made up 0.3% of Casdin Capital's portfolio in Q2 2026, its #31 holding.
  • Casdin Capital first reported a position in Intellia Therapeutics in Q3 2022 and has held it in 13 quarters since.
  • Casdin Capital's Intellia Therapeutics position peaked at $52M in Q2 2023.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.